Ratings by Oppenheimer (Jeff Jones)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/17/2026 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 6/16/2026 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2026 | Pelthos Therapeutics | PTHS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2026 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2026 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2026 | Whitehawk Therapeutics | WHWK | Maintain | Outperform (N/A) |
|
Details | ||
| 4/16/2026 | Aclaris Therapeutis | ACRS | New Coverage | Outperform (N/A) |
3.93 (4.76) |
21.12% | Details | |
| 4/2/2026 | Pharvaris B.V. | PHVS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Alumis Inc | ALMS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2026 | Pelthos Therapeutics | PTHS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2026 | Abeona Therapeutics | ABEO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2026 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/13/2026 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2026 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2026 | ArriVent BioPharma | AVBP | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2026 | Whitehawk Therapeutics | WHWK | New Coverage | Outperform (N/A) |
2.90 (4.45) |
53.45% | Details | |
| 1/26/2026 | Pelthos Therapeutics | PTHS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/20/2026 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/8/2026 | Ventyx Biosciences Inc | VTYX | Downgrade | Perform (Outperform) |
13.73 (14.00) |
1.97% | Details | |
| 1/6/2026 | Alumis Inc | ALMS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | ArriVent BioPharma | AVBP | Maintain | Outperform (Outperform) |
|
Details | ||
| 12/9/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2025 | Pelthos Therapeutics | PTHS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2025 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2025 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/30/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/30/2025 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 9/2/2025 | Pelthos Therapeutics | PTHS | New Coverage | Outperform (N/A) |
23.65 (29.10) |
23.04% | Details | |
| 8/27/2025 | Chemomab Therapeutics | CMMB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2025 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2025 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2025 | Y-mAbs Therapeutics | YMAB | Downgrade | Perform (Outperform) |
4.19 (8.61) |
105.49% | Details | |
| 7/21/2025 | ArriVent BioPharma | AVBP | Maintain | Outperform (N/A) |
|
Details | ||
| 6/27/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2025 | ArriVent BioPharma | AVBP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/29/2025 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/16/2025 | Chemomab Therapeutics | CMMB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2025 | Alumis Inc | ALMS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2025 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2025 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2025 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2025 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2025 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/26/2025 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2025 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2025 | ArriVent BioPharma | AVBP | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2025 | Pliant Therapeutics | PLRX | Downgrade | Perform (Outperform) |
7.79 (1.15) |
-85.24% | Details | |
| 1/30/2025 | Alumis Inc | ALMS | New Coverage | Outperform (N/A) |
6.53 (24.27) |
271.67% | Details | |
| 1/15/2025 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/13/2025 | Cellectar Biosciences | CLRB | Maintain | Perform (Perform) |
|
Details | ||
| 12/18/2024 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (Outperform) |
|
Details | ||
| 12/11/2024 | Cellectar Biosciences | CLRB | Downgrade | Perform (Outperform) |
1.28 (2.61) |
103.91% | Details | |
| 11/22/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2024 | Cellectar Biosciences | CLRB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2024 | Y-mAbs Therapeutics | YMAB | New Coverage | Outperform (N/A) |
11.14 (8.61) |
-22.71% | Details | |
| 11/15/2024 | Chemomab Therapeutics | CMMB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2024 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2024 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2024 | PMV Pharmaceuticals Inc. | PMVP | Upgrade | Outperform (Perform) |
1.78 (1.11) |
-37.64% | Details | |
| 11/7/2024 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/21/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/21/2024 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/14/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/11/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/11/2024 | Cellectar Biosciences | CLRB | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/27/2024 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/20/2024 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/10/2024 | ArriVent BioPharma | AVBP | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2024 | Pliant Therapeutics | PLRX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2024 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 7/24/2024 | Cellectar Biosciences | CLRB | Maintain | Outperform (N/A) |
|
Details | ||
| 7/22/2024 | ArriVent BioPharma | AVBP | New Coverage | Outperform (N/A) |
18.77 (32.83) |
74.91% | Details | |
| 6/18/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/7/2024 | Seres Therapeutics | MCRB | Downgrade | Perform (Outperform) |
1.14 (6.67) |
485.09% | Details | |
| 6/6/2024 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2024 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/30/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2024 | Perspective Therapeutics Inc | CATX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2024 | Pliant Therapeutics | PLRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2024 | Cellectar Biosciences | CLRB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2024 | Seres Therapeutics | MCRB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2024 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2024 | Pliant Therapeutics | PLRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2024 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2024 | Chemomab Therapeutics | CMMB | Upgrade | Outperform (Perform) |
0.74 (1.55) |
109.46% | Details | |
| 5/3/2024 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/22/2024 | Kymera Therapeutics | KYMR | New Coverage | Outperform (N/A) |
35.12 (101.77) |
189.78% | Details | |
| 4/1/2024 | Cellectar Biosciences | CLRB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2024 | Cellectar Biosciences | CLRB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/20/2024 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2024 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2024 | Ventyx Biosciences Inc | VTYX | Upgrade | Outperform (Perform) |
9.92 (13.73) |
38.41% | Details | |
| 3/6/2024 | Seres Therapeutics | MCRB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2024 | AN2 Therapeutics | ANTX | Downgrade | Perform (Outperform) |
20.00 (5.31) |
-73.45% | Details | |
| 2/6/2024 | Pliant Therapeutics | PLRX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2024 | Corbus Pharmaceuticals | CRBP | Maintain | Outperform (N/A) |
|
Details | ||
| 1/19/2024 | PMV Pharmaceuticals Inc. | PMVP | Downgrade | Perform (Outperform) |
1.80 (1.11) |
-38.33% | Details | |
| 1/19/2024 | PMV Pharmaceuticals Inc. | PMVP | Downgrade | Perform (Outperform) |
1.80 (1.78) |
-1.11% | Details | |
| 1/16/2024 | Seres Therapeutics | MCRB | Maintain | Outperform (N/A) |
|
Details | ||
| 1/9/2024 | Cellectar Biosciences | CLRB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2023 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2023 | AN2 Therapeutics | ANTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2023 | Pliant Therapeutics | PLRX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2023 | Seres Therapeutics | MCRB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/16/2023 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Outperform (N/A) |
|
Details | ||
| 10/10/2023 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/29/2023 | Fusion Pharmaceuticals | FUSN | New Coverage | Outperform (N/A) |
2.43 (21.55) |
786.83% | Details | |
| 9/11/2023 | Cellectar Biosciences | CLRB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2023 | Pliant Therapeutics | PLRX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/26/2023 | Seres Therapeutics | MCRB | New Coverage | Outperform (N/A) |
5.46 (6.67) |
22.16% | Details | |
| 6/7/2023 | Chemomab Therapeutics | CMMB | Downgrade | Perform (Outperform) |
1.70 (1.55) |
-8.82% | Details | |
| 6/1/2023 | Novan | NOVN | Downgrade | Perform (Outperform) |
1.19 (0.09) |
-92.44% | Details | |
| 5/23/2023 | Rain Therapeutics | RAIN | Downgrade | Perform (Outperform) |
9.93 (1.91) |
-80.77% | Details | |
| 5/16/2023 | Novan | NOVN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | Pliant Therapeutics | PLRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | Corbus Pharmaceuticals | CRBP | Upgrade | Outperform (Perform) |
8.87 (8.34) |
-5.98% | Details | |
| 4/18/2023 | Chemomab Therapeutics | CMMB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2023 | POINT Biopharma Global Inc. | PNT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2023 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/20/2023 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2023 | Pliant Therapeutics | PLRX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2023 | Cyclacel Pharmaceuticals | CYCC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2023 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/27/2023 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2022 | Cyclacel Pharmaceuticals | CYCC | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2022 | Evaxion Biotech | EVAX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Cellectar Biosciences | CLRB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2022 | POINT Biopharma Global Inc. | PNT | New Coverage | Outperform (N/A) |
7.43 (12.50) |
68.24% | Details | |
| 10/3/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2022 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2022 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2022 | Pliant Therapeutics | PLRX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2022 | Cellectar Biosciences | CLRB | Maintain | Outperform (N/A) |
|
Details | ||
| 7/20/2022 | Vascular Biogenics Ltd | VBLT | Downgrade | Perform (Outperform) |
2.05 (0.16) |
-92.2% | Details | |
| 7/19/2022 | Novan | NOVN | New Coverage | Outperform (N/A) |
2.42 (0.09) |
-96.28% | Details | |
| 7/18/2022 | Vascular Biogenics Ltd | VBLT | New Coverage | Outperform (N/A) |
2.09 (2.05) |
-1.91% | Details | |
| 7/18/2022 | Moleculin Biotech | MBRX | New Coverage | Outperform (N/A) |
1.65 (2.98) |
80.61% | Details | |
| 7/18/2022 | Evaxion Biotech | EVAX | New Coverage | Outperform (N/A) |
2.42 (3.10) |
28.1% | Details | |
| 7/18/2022 | Cyclacel Pharmaceuticals | CYCC | New Coverage | Outperform (N/A) |
1.22 (6.37) |
422.13% | Details | |
| 7/18/2022 | Cellectar Biosciences | CLRB | New Coverage | Outperform (N/A) |
0.43 (2.61) |
506.98% | Details | |
| 6/9/2022 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2022 | Rain Therapeutics | RAIN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/1/2022 | Rain Therapeutics | RAIN | New Coverage | Outperform (N/A) |
5.25 (1.91) |
-63.62% | Details | |
| 3/10/2022 | Chemomab Therapeutics | CMMB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2022 | PMV Pharmaceuticals Inc. | PMVP | Upgrade | Outperform (Perform) |
15.84 (1.11) |
-92.99% | Details | |
| 1/31/2022 | Ventyx Biosciences Inc | VTYX | New Coverage | Outperform (N/A) |
15.15 (14.00) |
-7.59% | Details | |
| 12/10/2021 | Pliant Therapeutics | PLRX | New Coverage | Outperform (N/A) |
15.14 (7.79) |
-48.55% | Details | |
| 12/8/2021 | Prometheus Biosciences Inc | RXDX | Upgrade | Outperform (Perform) |
29.92 (199.92) |
568.18% | Details | |
| 11/15/2021 | Chemomab Therapeutics | CMMB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2021 | Prometheus Biosciences Inc | RXDX | Downgrade | Perform (Outperform) |
37.00 (199.92) |
440.32% | Details | |
| 10/5/2021 | Prometheus Biosciences Inc | RXDX | New Coverage | Outperform (N/A) |
22.28 (199.92) |
797.31% | Details | |
| 8/19/2021 | PMV Pharmaceuticals Inc. | PMVP | New Coverage | Perform (N/A) |
34.32 (1.11) |
-96.77% | Details | |
| 5/7/2021 | Chemomab Therapeutics | CMMB | New Coverage | Outperform (N/A) |
19.85 (1.55) |
-92.19% | Details |
